Literature DB >> 10722576

Functional activities and immunoglobulin variable regions of human and murine monoclonal antibodies specific for the P1.7 PorA protein loop of Neisseria meningitidis.

J Wang1, G A Jarvis, M Achtman, E Rosenqvist, T E Michaelsen, A Aase, J M Griffiss.   

Abstract

The meningococcal PorA protein is considered a promising vaccine candidate. Although much is understood regarding the structure of PorA proteins, little is known about the structure-function relationships of PorA antibodies. The aim of this study was to compare the functional and molecular characteristics of a human monoclonal antibody (MAb) and three murine MAbs specific for the PorA P1.7 serosubtype. Murine MAbs 207,B-4 (immunoglobulin G2a [IgG2a]) and MN14C11.6 (IgG2a) were both bactericidal and opsonophagocytic for P1.7-expressing meningococci, whereas human MAb SS269 (IgG3) and murine MAb 208,D-5 (IgA) initiated neither effector function. Epitope mapping with synthetic peptides revealed that MAbs 207,B-4 and 208,D-5 recognized the sequence ASGQ, which is the same specificity motif that a previous study had established for SS269 and MN14C11.6. Nucleotide and amino acid sequence analyses of the variable regions of the four MAbs showed that the SS269 V(H) region belonged to the VH3 family and was approximately 70% homologous to those of the murine MAbs which were all from the 7183 family, whereas the SS269 V(L) region belonged to the Vlambda1-b family and was less than 40% homologous to those of the murine MAbs which were all members of the Vkappa1 family. The Fab fragment of SS269 was cloned and expressed in Escherichia coli and was shown by enzyme-linked immunosorbent assay analyses to bind as well as intact SS269 MAb to P1.7,16 serosubtype group B strain 44/76. We conclude that distinct differences exist in the effector function activities and variable region gene sequences of human and murine P1.7-specific MAbs despite their recognition of similar epitopes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10722576      PMCID: PMC97360          DOI: 10.1128/IAI.68.4.1871-1878.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  66 in total

1.  Human opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorB.

Authors:  A K Lehmann; A Halstensen; I S Aaberge; J Holst; T E Michaelsen; S Sornes; L M Wetzler; H Guttormsen
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

Review 2.  Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes.

Authors:  C E Frasch; W D Zollinger; J T Poolman
Journal:  Rev Infect Dis       Date:  1985 Jul-Aug

3.  Two V kappa germ-line genes related to the GAT idiotypic network (Ab1 and Ab3/Ab1') account for the major subfamilies of the mouse V kappa-1 variability subgroup.

Authors:  S Corbet; M Milili; M Fougereau; C Schiff
Journal:  J Immunol       Date:  1987-02-01       Impact factor: 5.422

4.  The differences between the structural repertoires of VH germ-line gene segments of mice and humans: implication for the molecular mechanism of the immune response.

Authors:  J C Almagro; I Hernandez; M del Carmen Ramirez; E Vargas-Madrazo
Journal:  Mol Immunol       Date:  1997 Nov-Dec       Impact factor: 4.407

5.  Opsonophagocytic and bactericidal activity mediated by purified IgG subclass antibodies after vaccination with the Norwegian group B meningococcal vaccine.

Authors:  A Aase; E A Høiby; T E Michaelsen
Journal:  Scand J Immunol       Date:  1998-04       Impact factor: 3.487

6.  Preferential utilization of the most JH-proximal VH gene segments in pre-B-cell lines.

Authors:  G D Yancopoulos; S V Desiderio; M Paskind; J F Kearney; D Baltimore; F W Alt
Journal:  Nature       Date:  1984 Oct 25-31       Impact factor: 49.962

7.  Tetravalent meningococcal polysaccharide vaccine groups A, C, Y, W 135: clinical and serological evaluation.

Authors:  J Armand; F Arminjon; M C Mynard; C Lafaix
Journal:  J Biol Stand       Date:  1982-10

8.  Effector functions of a monoclonal aglycosylated mouse IgG2a: binding and activation of complement component C1 and interaction with human monocyte Fc receptor.

Authors:  R J Leatherbarrow; T W Rademacher; R A Dwek; J M Woof; A Clark; D R Burton; N Richardson; A Feinstein
Journal:  Mol Immunol       Date:  1985-04       Impact factor: 4.407

9.  Relationship of human variable region heavy chain germ-line genes to genes encoding anti-DNA autoantibodies.

Authors:  H Dersimonian; R S Schwartz; K J Barrett; B D Stollar
Journal:  J Immunol       Date:  1987-10-01       Impact factor: 5.422

10.  Antigenic variation of the class I outer membrane protein in hyperendemic Neisseria meningitidis strains in the netherlands.

Authors:  A Bart; J Dankert; A van der Ende
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

View more
  4 in total

1.  Construction and functional activities of chimeric mouse-human immunoglobulin G and immunoglobulin M antibodies against the Neisseria meningitidis PorA P1.7 and P1.16 epitopes.

Authors:  Terje E Michaelsen; Øistein Ihle; Karen Johanne Beckstrøm; Tove K Herstad; Jan Kolberg; E Arne Høiby; Audun Aase
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

2.  Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding.

Authors:  Serena Giuntini; Donald C Reason; Dan M Granoff
Journal:  Infect Immun       Date:  2011-06-27       Impact factor: 3.441

3.  Human IgG1, IgG3, and IgG3 Hinge-Truncated Mutants Show Different Protection Capabilities against Meningococci Depending on the Target Antigen and Epitope Specificity.

Authors:  S Giuntini; D M Granoff; P T Beernink; O Ihle; D Bratlie; T E Michaelsen
Journal:  Clin Vaccine Immunol       Date:  2016-08-05

4.  Effect of complement Factor H on anti-FHbp serum bactericidal antibody responses of infant rhesus macaques boosted with a licensed meningococcal serogroup B vaccine.

Authors:  Serena Giuntini; Peter T Beernink; Dan M Granoff
Journal:  Vaccine       Date:  2015-11-10       Impact factor: 3.641

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.